Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
private:xigen | 761145 | Jun 4th, 2019 12:00AM | Xigen | 175 | 6.00 | Open | Biotechnology | Jun 4th, 2019 03:06PM | Jun 4th, 2019 03:06PM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Open | Open | CH | Xigen | Health Care Equipment & Services | |||||||
private:xigen | 761145 | Feb 17th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 17th, 2018 02:25PM | Feb 17th, 2018 02:25PM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 16th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 16th, 2017 08:15AM | Feb 16th, 2017 08:15AM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 15th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 15th, 2017 10:07AM | Feb 15th, 2017 10:07AM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 14th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 14th, 2017 01:50PM | Feb 14th, 2017 01:50PM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 13th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 13th, 2017 04:11PM | Feb 13th, 2017 04:11PM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 12th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 12th, 2017 04:15AM | Feb 12th, 2017 04:15AM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 11th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 11th, 2017 05:35AM | Feb 11th, 2017 05:35AM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 10th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 10th, 2017 06:43AM | Feb 10th, 2017 06:43AM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services | ||||||||||
private:xigen | 761145 | Feb 9th, 2018 12:00AM | Xigen | 135 | 6.00 | Open | Biotechnology | Feb 9th, 2017 08:57AM | Feb 9th, 2017 08:57AM | Xigen is a clinical phase biopharmaceutical company developing anti-inflammatory peptide based therapeutics expected to capture market share from both anti-TNF biologics and steroids. The company is uniquely positioned to exploit know-how on the targeted cellular delivery of optimised peptide-based products or small molecules employing proprietary carrier motifs | Xigen | Health Care Equipment & Services |